8,12,14-Triazatetracyclo[8.6.1.0^{2,7}.0^{13,17}]heptadeca-1(17),2(7),3,5,10,13,15-heptaene | 1036240-70-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 8,12,14-Triazatetracyclo[8.6.1.0^{2,7}.0^{13,17}]heptadeca-1(17),2(7),3,5,10,13,15-heptaene
• 英文别名: 8,12,14-triazatetracyclo[8.6.1.02,7.013,17]heptadeca-1(17),2,4,6,10,13,15-heptaene
• CAS: 1036240-70-6
• 化学式: C₁₄H₁₁N₃
• 分子量: 221.261
• InChiKey: KVJSVGONQQMVML-UHFFFAOYSA-N

物化性质

• 沸点：
  511.1±38.0 °C(predicted)
• 密度：
  1.318±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  聚合甲醛 、 2-(1H-pyrrolo[2,3-b]pyridin-4-yl)phenylamine 在 盐酸 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 0.5h， 生成 8,12,14-Triazatetracyclo[8.6.1.0^{2,7}.0^{13,17}]heptadeca-1(17),2(7),3,5,10,13,15-heptaene
  参考文献：
  名称：

  A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors

  摘要：

  Pictet-Spengler condensation of aldehydes or alpha-keto-esters with 4-(2-anilinophenyl)-7-azaindole (11) or deazapurine (12) gave high yields of the 3,4-fused cyclic compounds. SAR studies, by varying the substituted benzaldehyde components, lead to the discovery of a series of potent JAK2 kinase inhibitors. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.021

文献信息

• TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASE
  申请人：Bennani Yousseff

  公开号：US20100081645A1

  公开（公告）日：2010-04-01

  The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

  本发明涉及作为蛋白激酶抑制剂的化合物，特别是JAK家族激酶的抑制剂。该发明还提供了包含所述化合物的药用可接受组合物，以及使用该组合物治疗各种疾病、状况或障碍的方法。
• US8163732B2
  申请人：——

  公开号：US8163732B2

  公开（公告）日：2012-04-24
• [EN] TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASE<br/>[FR] COMPOSÉS HÉTÉROARYLE TRICYCLIQUES UTILES EN TANT QU'INHIBITEURS DE LA JANUS KINASE
  申请人：VERTEX PHARMA

  公开号：WO2008079521A2

  公开（公告）日：2008-07-03

  [EN] The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
  [FR] L'invention concerne des composés utiles en tant qu'inhibiteurs de protéine kinases, notamment des kinases de la famille JAK. L'invention concerne également des compositions pharmaceutiquement acceptables comprenant lesdits composés et des procédés d'utilisation des compositions dans le traitement de diverses pathologies, affections ou troubles.
• [EN] TETRACYCLIC CDK9 KINASE INHIBITORS<br/>[FR] INHIBITEURS TÉTRACYCLIQUES DE LA KINASE CDK9
  申请人：ABBVIE INC

  公开号：WO2015119712A1

  公开（公告）日：2015-08-13

  Disclosed are compounds of Formula (Ia), and pharmaceutically acceptable salts thereof, Formula (Ia), wherein X, Y, R1, R2, R3A, R3B, and R4 are as described herein. The compounds may be used as agents in the treatment of diseases, including cancer. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (Ia).
• A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors
  作者：Tiansheng Wang、Mark W. Ledeboer、John P. Duffy、Albert C. Pierce、Harmon J. Zuccola、Eric Block、Dina Shlyakter、James K. Hogan、Youssef L. Bennani

  DOI：10.1016/j.bmcl.2009.11.021

  日期：2010.1

  Pictet-Spengler condensation of aldehydes or alpha-keto-esters with 4-(2-anilinophenyl)-7-azaindole (11) or deazapurine (12) gave high yields of the 3,4-fused cyclic compounds. SAR studies, by varying the substituted benzaldehyde components, lead to the discovery of a series of potent JAK2 kinase inhibitors. (C) 2009 Elsevier Ltd. All rights reserved.